In this study, we retrospectively analyzed 56 Chinese NSCLC patients harboring EGFR mutations progressed on previous therapies in two medical centers, explored the treatment patterns, and evaluated the real‐world efficacy and safety of later‐line dacomitinib utilizing next‐generation sequencing (NGS). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.